{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:00:43Z","timestamp":1787680843979,"version":"build-2784847793"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>International and national guidelines recommend low-molecular-weight heparin for the treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the Caravaggio study is to assess whether oral apixaban is non-inferior to subcutaneous dalteparin for the treatment of acute proximal deep vein thrombosis and\/or pulmonary embolism in patients with cancer. The study is an investigator-initiated, multi-national, prospective, randomized, open-label with blind end-point evaluation (PROBE), non-inferiority clinical trial (NCT03045406). Consecutive patients are randomized to receive oral apixaban or subcutaneous dalteparin for 6 months. Apixaban is given at a dose of 10\u2009mg twice daily for the first 7 days and then 5\u2009mg twice daily; dalteparin is given at a dose of 200 IU\/kg for the first month and then 150 IU\/kg once daily. The primary outcome of the study is objectively confirmed recurrent VTE as assessed by a central independent adjudication committee unaware of study treatment allocation. The primary safety outcome is major bleeding defined according to the guidelines of the International Society of Thrombosis and Haemostasis. Assuming a 6-month incidence of the primary outcome of 7% with dalteparin and an upper limit of the two-sided 95% confidence interval of the hazard ratio below the pre-specified margin of 2.00, 1,168 patients will be randomized considering an up to 20% loss in total patient-years (\u03b2\u2009=\u200980%; \u03b1 one-sided\u2009=\u20090.025). The Caravaggio study has the potential, along with other recently performed or on-going studies, to make less cumbersome the management of VTE in patients with cancer by replacing parenteral with oral anticoagulation.<\/jats:p>","DOI":"10.1055\/s-0038-1668523","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T18:59:26Z","timestamp":1534186766000},"page":"1668-1678","source":"Crossref","is-referenced-by-count":127,"title":["Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study"],"prefix":"10.1055","volume":"118","author":[{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[{"name":"Internal Vascular and Emergency Medicine \u2013 Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"Internal Vascular and Emergency Medicine \u2013 Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany"},{"name":"Centre for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[{"name":"Institute of Hematology and BMT, Rambam Health Care Campus, Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Campanini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Azienda Ospedaliero Universitaria \u201cMaggiore della Carit\u00e0,\u201d Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cohen","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust Hospital, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Connors","sequence":"additional","affiliation":[{"name":"Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fontanella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Buon Consiglio Fatebenefratelli Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualberto","family":"Gussoni","sequence":"additional","affiliation":[{"name":"Fadoi Research Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden University, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lambert","sequence":"additional","affiliation":[{"name":"Division of Hematology, Thrombosis and Hemostasis Unit, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meyer","sequence":"additional","affiliation":[{"name":"H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Abreu de Sousa","sequence":"additional","affiliation":[{"name":"Surgical Oncology Department, Institut Portugu\u00eas Oncologie, Porto FG, EPE, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[{"name":"Departments of Pulmonary Hypertension, Thromboembolic Disease and Cardiology, Medical Center for Postgraduate Education, Otwock, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Verso","sequence":"additional","affiliation":[{"name":"Internal Vascular and Emergency Medicine \u2013 Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Vescovo","sequence":"additional","affiliation":[{"name":"Internal Medicine, S. Antonio Hospital, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Caravaggio Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2018,8,13]]},"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0038-1668523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T16:56:23Z","timestamp":1557161783000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0038-1668523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":0,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2018,9,14]]},"published-print":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0038-1668523","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]}}}